Attachment 4_60 day FRN

68887

Federal Register / Vol. 72, No. 234 / Thursday, December 6, 2007 / Notices
mail to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.

Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.

Proposed Project

Dated: November 29, 2007.
Carolyn M. Clancy,
Director.
[FR Doc. 07–5950 Filed 12–05–07; 8:45 am]

Gonococcal Isolate Surveillance
Project (GISP)—Revision—National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Background and Brief Description
CDC is requesting a 3-year revision
with change for this project. The
objectives of GISP are to monitor trends
in antimicrobial susceptibility of strains
of Neisseria gonorrhoeae in the U.S. and
characterize resistant isolates. GISP
provides critical surveillance for
antimicrobial resistance, allowing for
informed treatment recommendations.
This project began in 1986 as a
voluntary surveillance project and has
involved 5 regional laboratories and 30
publicly-funded, sexually transmitted
disease (STD) clinics around the
country. The STD clinics submit up to
25 gonococcal isolates per month to the
regional laboratories, which measure

Centers for Disease Control and
Prevention
[30Day–08–0307]

Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an e-

susceptibility to a panel of antibiotics.
Limited demographic and clinical
information corresponding to the
isolates are submitted directly by the
STD clinics to CDC.
During 1986–2006, GISP has
demonstrated the ability to effectively
achieve its objectives. The emergence of
resistance in the United States to
penicillin, tetracyclines, and now
fluoroquinolones was identified through
GISP and makes ongoing surveillance
critical. Increased prevalence of
fluoroquinolone-resistant N.
gonorrhoeae (QRNG) as seen in GISP
data has prompted the CDC to update
the treatment recommendations for
gonorrhea in the CDC’s Sexually
Transmitted Diseases Treatment
Guidelines, 2006 and to release an
MMWR article stating the CDC no
longer recommends fluoroquinolones
for treatment of gonococcal infections
(CDC, MMWR, Vol.56, No.14, 332–336).
Respondents are paid by Federal funds
through the CDC Comprehensive STD
Prevention Systems, Prevention of STDRelated Infertility, and Syphilis
Elimination Grant (CSPS), for their
participation in GISP network. The
estimated annualized burden for this
data collection is 8,628 hours.

ESTIMATED ANNUALIZED BURDEN HOURS
No. of responses per respondent

Avg. burden
per response
(in hours)

Form name

Clinic ....................................................................
Laboratory ............................................................

Form 1 .................................................
Form 2 .................................................
Form 3 .................................................

30
5
5

240
1,452
48

11/60
1
12/60

Total ..............................................................

..............................................................

40

..........................

..........................

Dated: November 28, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer.
[FR Doc. E7–23633 Filed 12–5–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–08–0263]

mstockstill on PROD1PC66 with NOTICES

No. of
respondents

Type of respondent

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the

VerDate Aug<31>2005

18:57 Dec 05, 2007

Jkt 214001

Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be

PO 00000

Frm 00031

Fmt 4703

Sfmt 4703

collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Requirements for a Special Permit to
Import Cynomolgus, African Green, or
Rhesus Monkeys into the United
States—Extension—National Center for
Preparedness, Detection, and Control of
Infectious Diseases (NCPDCID), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
CDC is requesting OMB approval to
continue its data collection,
‘‘Requirements for a Special Permit to

E:\FR\FM\06DEN1.SGM

06DEN1

68888

Federal Register / Vol. 72, No. 234 / Thursday, December 6, 2007 / Notices

Import Cynomolgus, African Green, or
Rhesus Monkeys into the United
States’’, for another three years. This
data collection is currently approved
under OMB Control No. 0920–0263.
There are no revisions proposed to the
currently approved information
collection request.
A registered importer must request a
special permit to import Cynomolgus,
African Green, or Rhesus monkeys. To
receive a special permit to import
nonhuman primates, the importer must
submit a written plan to the Director of
CDC which specifies steps that will be
taken to prevent exposure of persons
and animals during the entire
importation and quarantine process for
the arriving nonhuman primates.
Under the special permit
arrangement, registered importers must
submit a plan to CDC for importation

and quarantine if they wish to import
the specific monkeys covered. The plan
must address disease prevention
procedures to be carried out in every
step of the chain of custody of such
monkeys, from embarkation in the
country of origin to release from
quarantine. Information such as species,
origin and intended use for monkeys,
transit information, isolation and
quarantine procedures, and procedures
for testing of quarantined animals is
necessary for CDC to make public health
decisions. This information enables
CDC to evaluate compliance with the
standards and to determine whether the
measures being taken are adequate to
prevent exposure of persons and
animals during importation. CDC will
monitor at least 2 shipments to be
assured that the provisions of a special
permit plan are being followed by a new

permit holder. CDC will assure that
adequate disease control practices are
being used by new permit holders
before the special permit is extended to
cover the receipt of additional
shipments under the same plan for a
period of 180 days, and may be renewed
upon request. This extension eliminates
the burden on importers to repeatedly
report identical information, requiring
submission only of specific shipment
itineraries and information on changes
to the plan which require approval.
Respondents are commercial or notfor-profit importers of nonhuman
primates. The burden represents full
disclosure of information and itinerary/
change information, respectively. There
are no costs to respondents except for
their time to complete the requisition
process. The annualized burden for this
data collection is 13 hours.

ESTIMATE OF ANNUALIZED BURDEN HOURS
Number of
respondents

Respondents

Average burden
per response
(in hours)

Total
burden

Businesses (limited permit) .....................................................................
Businesses (extended permit) .................................................................
Organizations (limited permit) ..................................................................
Organizations (extended permit) .............................................................

5
1
3
12

2
3
2
2

30/60
10/60
30/60
10/60

5
5
3
4

Total ..................................................................................................

..........................

..........................

..........................

13

Dated: November 29, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–23634 Filed 12–5–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
Notice of Hearing: Reconsideration of
Disapproval of New York State
Children’s Health Insurance Program
(SCHIP) State Child Health Plan
Amendment (SPA) #10
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice of hearing.
AGENCY:

mstockstill on PROD1PC66 with NOTICES

Number of responses per respondent

SUMMARY: This notice announces an
administrative hearing to be held on
January 16, 2008, at the CMS New York
Regional Office, 38–110A, 26 Federal
Plaza, New York, New York 10278, to
reconsider CMS’ decision to disapprove
New York SCHIP SPA #10.
Closing Date: Requests to participate
in the hearing as a party must be

VerDate Aug<31>2005

18:57 Dec 05, 2007

Jkt 214001

received by the presiding officer by
December 21, 2007.
FOR FURTHER INFORMATION CONTACT:
Kathleen Scully-Hayes, Presiding
Officer, CMS, Lord Baltimore Drive,
Mail Stop LB–23–20, Baltimore,
Maryland 21244, Telephone: (410) 786–
2055.
SUPPLEMENTARY INFORMATION: This
notice announces an administrative
hearing to reconsider CMS’ decision to
disapprove New York SCHIP SPA #10
which was submitted on April 12, 2007,
with additional information submitted
on May 9, 2007, and August 27, 2007,
and disapproved on September 7, 2007.
This SPA would have increased the
financial eligibility standard for the
State’s separate SCHIP from the current
effective family income eligibility level
at or below 250 percent of the Federal
poverty level (FPL) to an effective
family income eligibility level at or
below 400 percent of the FPL. The SPA
also would have imposed a 6-month
waiting period from the date of last
insurance coverage for children with
family incomes above 250 percent of the
FPL, with certain listed exceptions.
The CMS disapproved the SPA
because it would result in a child health
plan that did not comport with the

PO 00000

Frm 00032

Fmt 4703

Sfmt 4703

requirements of sections 2101(a),
2102(a), and 2102(b)(3)(C) of the Social
Security Act (the Act). These
requirements provide that funding must
be used to provide coverage to
uninsured, low-income children in an
effective and efficient manner that is
coordinated with other sources of health
benefits coverage, that the State plan
includes effective outreach procedures
to enroll all eligible uninsured children,
and that the coverage made available
does not merely substitute for private
coverage. This disapproval is also
consistent with the August 17, 2007,
letter to State Health Officials clarifying
how CMS believes these existing
statutory requirements should be
applied by all States expanding SCHIP
effective eligibility levels above 250
percent of the FPL.
The following will be at issue at the
hearing:
• Whether the State has demonstrated
that SPA #10 is consistent with the
requirement in section 2101(a) of the
Act for effective and efficient program
operation. SPA #10 would require that
the State devote limited SCHIP funding
to children with higher effective family
incomes when the program has not
enrolled substantially all of the core

E:\FR\FM\06DEN1.SGM

06DEN1